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Abstract. Radiation therapy (RT) alone has been considered for a long time as the standard 
therapeutic option for limited stage FL, due to its high efficacy in terms of local disease control 
with a quite significant proportion of “cured” patients (without further relapses at 10-15 years). 
Multiple therapeutic choices are currently accepted for the management of early stage FL at 
diagnosis, and better staging procedures as well as better systemic therapy partially modified the 
role of RT in this setting. RT has also changed in terms of prescribed dose as well as treatment 
volumes. In this review, we present and discuss the current role of RT for limited stage FL in 
light of the historical data and the modern RT concepts along with the possible combination with 
systemic therapy. 
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Introduction. Approximately 25% of patients with 
follicular lymphoma (FL) present with stage I-II 
disease, the so-called “limited stage”, defined as 
either a single lymph nodal site or a limited 
lymphatic region without bone marrow 
involvement.
1,2
 For a long time, the preferred 
treatment approach has been radiation therapy 
(RT) alone, on the basis of several retrospective 
single-institution series showing a high rate of 
local disease control, with a proportion of patients 
(45%) achieving long-term survival without 
relapses (the only situation where FL has been 
defined as “curable”).3-16 However, there is a lack 
of prospective data, and very few retrospective 
studies have been conducted to compare this 
treatment modality versus others, including a 
“wait and see” policy. Recent advances in staging 
and new therapeutic options partially modified this 
scenario, and nowadays only 35-50% of patients 
are being offered RT alone at diagnosis in Unites 
States.
17
 This reflects a common pattern of 
practice among hematologists and radio-
oncologists worldwide, given the extensive 
portfolio of therapeutic options. At the same time, 
RT has evolved towards the use of smaller fields 
and lower doses, with optimal control rates and 
minimal toxicity;
18
 data on the combination of low 
dose RT and rituximab became also available.
19
 
Aim of this review is to present and discuss the 
current role of RT in this setting. 
 
History of RT Use and Current Indications. The 
definition of “limited” versus “generalized” FL 
depends on the definition of “limited” and by the 
intensity of staging investigations performed at 
diagnosis.
20
 Limited disease usually means stage I 
and contiguous stage II, as some stage II may be 
considered as generalized due to the presence of 
extended multiple sites disease (for example 
abdominal presentations). The presence of bone 
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marrow involvement classically defines stage IV, 
however the presence of bone marrow minimal 
involvement (BCL-2/IgH rearrangement detected 
by polymerase chain reaction-PCR) has an 
uncertain significance. Approximately 60-80% of 
patients with presumed stage I-II disease may have 
circulating or bone marrow cells with Bcl-2/IgH 
rearrangement, with an unclear effect on 
prognosis.
21
 Most of the historical series reporting 
on outcomes following RT refer to a stage 
stratification based on clinical/radiological 
staging. An historical series by Goffinet et al. 
reported on 206 patients with “nodular” lymphoma 
where 31% of patients had stage I-II based on 
physical examination and imaging, but only 12% 
remained stage I-II after laparotomy/splenectomy 
for marrow negative patients.
22
 As the quality of 
imaging improved, together with the introduction 
of new modalities such as positron emission 
tomography (PET), a lower proportion of patients 
now present with stage II disease. In fact, truly 
localized disease is probably a rare entity, and few 
reports in the literature have sufficient magnitude 
for comparing clinical results after modern 
staging, since the patients’ accrual for most series 
took many years and the follow up interval for 
detecting relapses is at least 10 years.
20
 After RT 
the majority of the lesions completely regress, and 
local relapse at an irradiated site is rare. 
Recurrences usually occur distantly from the RT 
site and are rare after 10 years (1-11%). Probably 
the largest retrospective study on stage I or II FL 
included 568 patients diagnosed between 1973 and 
2004, and was based on Surveillance 
Epidemiology and End Result (SEER) data.
23
 In 
34 % of these patients, RT was used as the initial 
treatment; the group receiving RT at the onset had 
higher rates of disease-specific survival (DSS) at 5 
years (90 vs. 81%), 10 years (79 vs. 66%), 15 
years (68 vs. 57%), and 20 (63 vs. 51%) years, 
respectively. The rationale for the use of RT is 
thus based on the results of large mono-
institutional experiences or observational cohort 
studies, which has been incorporated by 
international cooperative groups and clinical 
guidelines such as the National Comprehensive 
Cancer Network (NCCN), the European Society of 
Medical Oncology (ESMO) and the Italian Society 
of Hematology-Bone Marrow Transplantation 
Group (SIE-GITMO).
24-26
 Table 1 summarizes the 
results of the major studies on RT use for limited 
stage FL at diagnosis. Despite these indications, a 
recent observational study by the National 
Lymphocare project showed that variable 
treatment approaches are currently proposed to 
stage I-II FL patients: “wait and see” policy, 
chemotherapy, RT, Rituximab alone or systemic 
therapy plus RT.
17
 All these alternative treatments 
actually have excellent outcomes (median follow-
up of 57 months). Interestingly, a subgroup of 206 
patients who were rigorously staged, with bone 
marrow aspirate and biopsy and CT scan or PET 
scan or both, had increased survival. Among this 
patients' cohort approximately 30% with 
confirmed stage I at PET-CT were offered RT 
alone as frontline therapy. With regards to the 
“wait and see” approach, researchers from 
Stanford University previously reported on a series 
of 43 selected patients with limited stage FL 
untreated at diagnosis who had a comparable 
outcome with those treated with RT alone.
27
 
Soubeyran et al.
28
 also studied 43 patients with 
stage I follicular lymphoma been completely 
resected; 26 patients, accrued over an 11-years 
period, were selected for a “wait-and-see” policy 
(those had the lowest suspicion of residual 
disease): with a median follow up of 6.3 years, 
13/26 (50%) relapsed, 6 locally and 7 distantly.  
Nowadays, the evidence in favor of the use of 
RT at diagnosis for limited stage FL still relies on 
its curative potential: as shown in Table 1, 
historical series of more than 100 patients showed 
progression-free survival (PFS) rates at 10 years 
ranging from 40 to 59%, and overall survival rates 
of 58-86%.
5,7,9,10,14,15
 These series include patients 
treated as long ago as the 1970s, with implications 
regarding histological classification, staging 
procedure and systemic therapy. Despite the 
relative similarity of the outcome projections at 10 
years, differences also exist among the reported 
series with regards to radiation volumes and dose, 
with a potential impact on late toxicity. The long-
term survival outcome after RT alone for properly 
staged stage I-II FL patients, treated with modern 
fields and doses, is yet to be reported. Overall 
survival (OS) has apparently increased in recent 
years due to the introduction of Rituximab also for 
limited stage FL,
17,29
 but PFS after RT alone 
remained in this range, with approximately 45% of 
patients without relapses at 10 years. 
 
RT Volumes. From previously cited series, 
limited radiation volumes (involved field RT: 
IFRT) seem to be sufficient for disease control in
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Table 1. Clinical outcomes of RT for limited stage FL. 
Authors Pts (n) 
Total RT 
dose (Gy) 
RT Volume 
Follow-up 
yrs. 
PFS (%) OS (%) 
Chen et al, 19793 26 35-45 IF or EF  6-yr 83 NS 
Paryani et al, 19834 124 35-50 IF,EF,TNI 5,5 
5-yr 62 
10-yr 54 
15-yr 42 
5-yr 84 
10-yr 68 
15-yr 40 
Gospodarowicz et al, 19845 248 
20-50 (<35 
Gy in 86%) 
IF 12 
5-yr 56 
10-yr 53 
5-yr 73 
10-yr 58 
Epelbaum et al, 19926 48 30-50 IF, EF 6,3 
5-yr 71 
10-yr 57 
5-yr 83 
10-yr 68 
Vaughan Hudson et al, 19967 208 35 NS 10 10-yr 47 10-yr CSS 71-84 
Pendlebury et al, 19958 58 30-54 IF,EF NS 
5-yr 59 
10-yr 43 
5-yr 93 
10-yr 79 
MacManus et al, 19969 177 35-44 IF,EF,TNI 7,7 
5-yr 55 
10-yr 44 
15-yr 40 
5-yr 82 
10-yr 64 
15-yr 44 
Stuschke et al, 199710 117 26 + 10 EF,TNI 5,7 
5-yr 71 
10-yr 59 
5-yr 86 
10-yr 86 
Kamath et al, 199911 72 NS IF,EF,TNI NS 
5-yr 62 
10-yr 59 
15-yr 47 
5-yr 73 
10-yr 46 
15-yr 40 
Wilder et al, 200112 80 26-50 IF,EF 19 
5-yr 63 
10-yr 57 
15-yr 41 
5-yr 82 
10-yr 65 
15-yr 43 
Ott et al, 200313 58 26-50 IF,EF,TNI 8,8 
5-yr 74 
10-yr 64 
5-yr 86 
10-yr 69 
Neumann et al, 200314 116 20-50 IF,EF,TNI 4 
5-yr 62 
10-yr 48 
5-yr 76 
10-yr 51 
Petersen et al, 200415 460 16-47.5 IF 12.5 
5-yr 56 
10-yr 41 
5-yr 79 
10-yr 62 
Eich et al, 200916 65 26-46 IF,EF,TNI 9.1 
5-yr 55 
10-yr 37 
5-yr 86 
10-yr 55 
Abbreviations: IF (involved field); EF (extended field); TNI (total nodal irradiation); NS (not specified); CSS (cancer specific survival). 
 
 
Figure 1. Example of involved site radiotherapy in a case of a 43 years old male patient affected with limited stage FL (right inguinal and 
crural nodes). 
 
limited stage FL. In fact, no differences in OS 
were reported by series including patients treated 
with either limited or more extensive radiation 
fields (e.g. extended fields RT (EFRT) or total 
nodal irradiation (TNI)). However, as expected, 
many retrospective studies observed that larger 
volumes resulted in higher PFS rates.
4,6
 For 
example, the Stanford University group showed 
that Total Lymphoid Irradiation (TLI) was 
associated with a lower relapse rate at 5 and 10 
years (23% and 33%, respectively) compared with 
treatment to one side of the diaphragm only (52% 
and 64%, respectively).
4
 In these series, two thirds 
of deaths were due to other causes. At this regard, 
there are concerns that larger irradiation volumes 
might increase the risk of acute (e.g. 
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hematological or gastrointestinal symptoms) and 
late (e.g. second tumors or cardiovascular disease) 
toxic effects.
9
 Wilder et al.
12
 found no differences 
in cause-specific survival (15 years: 59% vs. 72%) 
and OS (15 years: 49% vs. 40%) between patients 
treated with EFRT vs. IFRT. A large proportion of 
relapses (93%) involved the side of the diaphragm 
opposite the original site of disease and 59% 
exclusively affected the opposite side of the 
diaphragm. A German prospective multicenter 
phase II trial study investigated the influence of 
EF and total lymphoid irradiation on PFS, pattern 
of relapse and OS, showing no difference at 5 and 
7 years between larger or smaller fields.
10
 
IFRT for FL is traditionally defined as for 
Hodgkin’s lymphoma, including clearly defined 
“regions” of the Ann Arbor classification 
system,
18
 but a modern approach to more limited 
radiation fields has been developed in recent years 
following radical changes occurred for the 
radiation treatment of HL, introducing the so-
called “involved nodal radiotherapy” (INRT) 
volumes.
30
 Unlike classic IFRT, INRT limits the 
treatment to only pre and post-chemotherapy 
involved nodal volumes. INRT is based on optimal 
pre-treatment imaging, taking into account pre-
chemotherapy CT and FDG-PET scans. However, 
this concept does not simply apply to FL, as INRT 
was developed for Hodgkin’s Lymphoma (HL) for 
consolidation after chemotherapy, and not as a 
single modality curative approach. In FL, nodes 
that are “at risk” (i.e., minimally involved nodes 
that may be negative on PET imaging but involved 
by microscopic disease), should be included 
within radiation volumes in the absence of an 
active systemic therapy, as the likelihood of 
involvement is too great to be ignored.
20
 The 
International Lymphoma Radiation Oncology 
Group (ILROG) has thus developed specific 
consensus guidelines for the delineation of RT 
volumes for non-Hodgkin’s lymphomas that are 
slightly different from those developed for HL:
31
 
the new concept, defined as “involved site 
radiotherapy” (ISRT), has been adopted by the 
NCCN and provides the basis for the current RT 
protocols.
24
 Although ISRT for NHL has not yet 
been validated through randomized trials, single-
arm and retrospective data suggest comparable 
disease control to IFRT. A study from Vancouver 
looked retrospectively at patients that with limited 
stage FL treated either with IFRT or with a smaller 
field limited to the involved site.
32
 At a median 
follow-up of 7.5 years, both the larger and the 
smaller fields yielded excellent local control. Only 
1% of patients who were treated with the smaller 
fields approach relapsed in adjacent regional nodes 
and there was no difference with respect to distant 
failure between the two groups (involved site 
32 %, IFRT 38%). 
In this context, the clinical target volumes 
identification for FL now requires consideration of 
quality/accuracy of imaging, expected patterns of 
spread, potential subclinical disease and adjacent 
organs at risk constraints. ISRT actually maintains 
the original intent of IFRT, but reduces the 
planned radiation volume trough an optimized use 
of modern imaging. This change in RT volumes 
reduces radiation exposure to organs at risk, 
reducing as well the risk of late toxicity. 
 
RT Dose. The curative radiation dose for localized 
FL has been in the range 36-45 Gy for a long time, 
as derived from early studies (Table 1). Within 
this dose range, local control reached 
approximately 90-95%, as already reported by 
Fuks and Kaplan in 1973.
33
 A series of studies 
from Princess Margaret Hospital further defined 
dose-response curves for both DLBCL and FL.
34
 
For patients with medium or large-bulk disease 
(2.5-5 cm and >5 cm, respectively), 50% local 
control rate was achieved with a dose of 20 Gy, 
reaching 70% at 30 Gy and 80% at 40 Gy, with a 
plateau thereafter. For FL, doses in the range 25-
35 Gy are able to obtain a local control rate 
>90%.
5
 Similar data were reported in a more 
contemporary series from University of Florida,
11
 
with 30 Gy achieving local control in again >90% 
of patients. Stuschke et al.
10
 recommended a total 
dose of 30 Gy to lymph nodes with suspected 
subclinical disease and a total dose of 36-44 Gy to 
macroscopically involved lymph nodes. 
Nevertheless, in the “old” series many 
investigators noted that a significant number of 
patients with FL were controlled with a dose of 
<30 Gy.
35
 These findings led to the design of a 
randomized phase III study from the United 
Kingdom, comparing the standard dose of 40-45 
Gy to 24 Gy in 361 involved sites of patients with 
indolent lymphomas (mostly FL and marginal 
zone B-cell lymphomas -MZL- in early stages).
36
 
At a median follow-up of 5.6 years, there was no 
difference in overall response (93% and 92%, 
respectively) between the standard and the lower 
dose arms. There was also no difference in PFS or 
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OS, and 24 Gy was thus established as the 
standard dose for treating limited-stage indolent 
non-Hodgkin’s lymphomas, including FL. 
Very low-dose RT, largely used in the past 
years as palliation with total body irradiation, has 
also been proved to be effective in indolent NHL, 
particularly in FL. A radiation schedule of 4 Gy in 
2 fractions was firstly shown to be highly effective 
when used for palliation of advanced-stage, 
relapsing, or even post multiple chemotherapy 
refractory patients with indolent lymphomas by 
Ganem et al.
37
 Girinsky et al. subsequently 
achieved an overall response rate (ORR) of 81%, 
with a median duration of response of 24 months 
and freedom from local progression of 56% at two 
years, on 48 patients classified as low-grade NHL 
according to the Working Formulation.
38
 A 
subsequent prospective study by Johanssonn et al. 
including 15 patients with FL confirmed a high 
ORR (87%), with a median duration of response 
of 22 months.
39
 A further study on 109 patients, 
including 98 FL, previously treated with multiple 
lines of chemotherapy, reported an ORR of 92%, 
and median duration of response and time to 
progression of 42 and 25 months, respectively.
40 
Murthy et al. also assessed the impact of low-dose 
RT on patients' quality of life (European 
Organization for Research and Treatment of 
Cancer EORTC QLQ-C30), highlighting that low-
dose RT was very well tolerated and had almost 
no impact.
41
 Regarding predictive/prognostic 
factors, Girinsky et al. reported lower PFS rates 
for patients previously treated with more than two 
chemotherapy lines, and lower response rates for 
masses larger than 5 cm and patients treated at age 
> 65 years.
38
 Haas et al.
40
 found no correlation 
between age, sex, follicular lymphoma grade, RT 
regimen, number of previous regimens and 
previous history, number of positive sites or 
largest lymphoma diameter and response rate; 
conversely, Russo et al.
42
 showed that patients 
aged <50 years had lower PFS rates (and also 
those with CLL histology in comparison with 
other indolent NHL subtypes).  
Following these positive results, a randomized 
phase III trial was then conducted to compare 
standard dose (24 Gy/12 fractions) vs. low dose 
RT (4 Gy/2 fractions) as frontline radical or 
palliative treatment in FL and MZL.
43
 A total of 
614 sites in 548 patients with FL (and some with 
MZL) were prospectively randomized to receive 
either 24 Gy or 4 Gy. In 60% of patients, the intent 
of RT was considered as palliative, and in 40% as 
curative. This study showed a higher ORR (81% 
vs. 74%) and 2-year PFS rate (94% vs. 80%) for 
24 Gy vs. 4 Gy; thus 24 Gy remained the standard 
RT dose for the curative treatment of limited stage 
FL and MZL when radiation is administered as 
exclusive therapy. Table 2 summarizes the results 
of selected studies testing very low-dose RT for 
limited stage FL. 
 
Combination with Chemotherapy. As 
underlined in a recent comprehensive review,
20
 
almost no studies reporting on the combination of 
RT and systemic therapy for stage I-II FCL were 
adequately powered to test for a difference in 
survival between RT vs. RT plus chemotherapy, 
given the rarity of early stage FCL. The British 
National Lymphoma Investigation (BNLI) 
conducted a trial between 1974 and 1980, where 
patients with Ann Arbor Stage I-II disease were 
treated with involved field RT alone to 35 Gy. 
Patients were then randomized to no further 
therapy (n=55) vs. chlorambucil 0.2 mg/kg/day 
orally for 8 weeks, followed by 0.1 mg/kg/day 
for16 weeks (n=50). No significant differences in 
PFS or OS were detected between the two arms.
44
 
One large non-randomized trial has been reported 
by Seymour et al.,
45
 on 85 patients with stage I–II 
FL who received 3 cycles of chemotherapy 
followed by involved field RT (30-40 Gy) 
followed by cyclophosphamide, vincristine, 
prednisone, and bleomycin (COP-Bleo) for 7 
cycles; patients with extra-nodal involvement, 
bulky disease (>5 cm.), or an elevated LDH also 
received doxorubicin (CHOP-Bleo). Ten-year 
freedom from treatment failure was 76%, and OS 
82%. These appear both substantially better than 
results reported above for RT alone (however, this 
was not a randomized trial, and similar results 
have not been reported by others). Guadagnolo et 
al.
46
 reported on a series of 106 patients treated 
with IFRT +/- chemotherapy. There was no 
significant difference in PFS between patients who 
received chemotherapy and those who did not. The 
10- and 15-year PFS rates were 47% and 43%, and 
46% and 31% for patients treated with RT and 
with combined chemotherapy and RT, respectively 
(p=0.72). Patients were treated between 1972 and 
2000, and interestingly, with very long-term 
follow-up, the incidence of secondary 
malignancies was not increased in this population 
in comparison with the expected incidence.  
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Table 2. Studies on low dose RT for FL. 
Authors 
Pts 
(n) 
Histology Stage Dose/fx 
Response 
rate 
Survival Toxicity 
Girinsky et al, 200138  48 Low grade 
I 15% 
II 23% 
III 27% 
IV 31% 
4 Gy/2 fx 
 
CR 57% 
PR 24% 
Median duration of 
response: 24 months 
2yr FFLP 56% 
No events 
Johannsson et al, 200239  15 
Indolent 
NHL 
Advanced 4 Gy/2 fx 
CR 74% 
PR 13% 
Median duration of 
response: 22 months 
No events 
Haas et al, 200340  109 
Indolent 
NHL 
(FL=98), 
Advanced 
(52%bulky) 
4 Gy/2 fx 
CR 61% 
PR 31% 
SD 6% 
PD 2% 
Median duration of 
response: 42 months 
Median TTLP: 25 months 
PFS1yr 50% 
PFS2yrs 33% 
PFS3yrs 25% 
PFS5yrs 10% 
No events 
Murthy et al, 200841  29 
Indolent 
NHL 
Advanced 4 Gy/2 fx ORR 86% NR No events > G2 
Russo et al, 201242  127 
Indolent 
NHL 
(including 
CLL) 
I (16%) 
II (10%) 
III (31%) 
IV 43%) 
4 Gy/2 fx 
 
CR 57% 
PR 25% 
TTP 13.6 months 
 
No events 
Abbreviations: NHL (non-Hodgkin’s lymphoma); FFLP (freedom from local progression); TTLP (time to local progression); PFS 
(progression free survival); CLL (chronic lymphatic leukemia); CR (complete response); PR (partial response); SD (stable disease); PD 
(progressive disease), ORR (overall response rate); NR (not reported). 
 
A retrospective series by Michallet et al. also
reported a substantial equivalence in OS for 
patients treated at diagnosis with either 
chemotherapy-RT or RT alone; a possible 
explanation for the observed differences in PFS 
but not OS for the combination of chemotherapy 
and RT could be the good response rate at relapse 
to R-chemotherapy for patients who only received 
RT as first line therapy at diagnosis. OS was better 
for patients treated after the year 2000. A small 
group was also treated with chemoimmunotherapy 
upfront, with excellent results.
29
 
 
Combination with anti-CD20. As previously 
mentioned, the role of combined radio-
chemotherapy in the management of limited-stage 
FL is uncertain, due to the reported significant 
toxicity, unclear superiority, and the fact that these 
studies were conducted in the pre-rituximab era. 
The introduction of the anti-CD20 antibody 
rituximab has radically changed the therapeutic 
options for patients with FL.
47,48
 Rituximab has 
been proposed as an alternative option to the 
watchful waiting approach in low-tumor burden 
advanced stage FL, and a recent multicenter 
randomized trial has shown the advantage of 
Rituximab vs. watch and wait for policy regarding 
PFS, although no advantages have been reported 
for OS.
49
 These promising results, as well as 
another phase II clinical trials, demonstrated a 
significant single agent activity of rituximab in 
both pretreated and untreated patients with FL.
50
 
Furthermore, rituximab may contribute in 
eliminating the minimal residual disease in 
advanced disease
51
 and may enhance radiation-
induced apoptosis and cell growth delay.
52,53
 The 
findings of these studies on advanced stage-low 
tumor burden FL cannot be directly extended to 
the limited stage. Nonetheless they provide the 
basis for a theoretically successful combination 
with RT for stage I-II disease, by increasing 
disease control outside radiation fields. At this 
regard, a case-cohort study by Ruella et al.
19
 
showed for the first time that 4 doses of Rituximab 
followed by IFRT was a very well tolerated 
regimen able to reach a 10-year PFS rate of 
64.6%, in comparison to the 50.7% rate achieved 
in control patients treated with RT alone for stage 
I-II FL (p<0.05). This superiority in PFS might 
translate into better long-term disease control and 
cure rate. Interestingly, this study also showed that 
among Rituximab-RT-treated patients, those with 
minimal bone marrow disease at baseline (PCR 
positivity) were at higher risk of relapse (6/10, 
60%) compared to those with PCR negativity 
(4/23,17%), despite the use of Rituximab. This 
data stresses the importance of the evaluation and 
monitoring of molecular disease also in patients 
with low tumor burden, as this is probably one of 
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the most important prognostic factors for relapse 
after both RT alone and RT-Rituximab. In fact, 
even with the addition of rituximab to RT, about 
35% of patients do progress, and in particular 
patients with molecular disease positivity at 
diagnosis are at increased risk of relapse. Similar 
data were reported by Pulsoni et al. in a previous 
study, then updated.
54,55
 Fifty-seven consecutive 
patients treated with RT for limited stage FL were 
analyzed, and 38/57 (66.7%) had the molecular 
disease either in the bone marrow or peripheral 
blood despite a negative biopsy. Of these, 19/38 
(50%) became negative after RT, and some 
patients with persistent positivity received 
Rituximab. However, the presence of molecular 
disease at diagnosis resulted to be associated with 
a worse prognosis despite the use of RT followed 
by Rituximab (10/11 relapses were PCR positive). 
Therefore, it could be reasonable in the future 
either to increase the initial dose of rituximab, 
with four additional doses after RT or to start 
maintenance at RT. This approach might be 
considered at least in patients presenting with the 
PCR-detectable disease at baseline. The MD 
Anderson Cancer Center is currently enrolling 
patients in a clinical trial offering a 2-yr 
maintenance after induction with rituximab-RT 
(NCT01473628). The MIR study, a phase II study 
of the German Low-Grade Lymphoma Study 
Group (GLSG), was designed with the first block 
of 4 rituximab doses, a 4 weeks gap with a 
restaging CT / planning CT of the involved nodal 
region in week 7 and then another block of 4 
rituximab doses given concurrently with IFRT (40 
Gy for macroscopic tumor or 30 Gy in case of 
CR). The primary endpoint of the study was PFS 
at two years, and preliminary data presented at the 
American Society of Hematology (ASH) 2012 
meeting were encouraging, with a 2-yr PFS of 
90%.
56
 
Conclusions and Future Perspectives. A 
moderate dose (24 Gy) Involved-site RT (ISRT) 
may cure approximately half of limited stage FL 
patients, with negligible acute and apparently no 
virtual late toxicity. Small radiation volumes are 
currently used for all localizations, including 
extra-nodal presentations. A high response rate is 
also achievable with very low dose RT (2 x 2 Gy), 
even in heavily pretreated patients; this option is 
now widely acknowledged to be very active as 
palliative treatment or frontline choice in selected 
cases. The combination of RT and anti-CD20 
antibodies seems promising and might offer better 
long-term disease control; however, patients with 
molecular disease in the bone marrow or 
peripheral blood at diagnosis seem to be at high 
risk of relapse despite the use of RT plus 
rituximab. A trend towards a better survival is 
expected for patients staged with modern imaging, 
particularly with the use of CT-PET. Future 
perspectives in this field include the combination 
of RT with new targeted agents and 
immunotherapy, especially for those patients 
considered at higher risk of relapse; new 
generation anti-CD20 antibodies will probably 
further improve results. Limitations in the use of 
RT at diagnosis consist of the variety of 
therapeutic options for limited stage FL, including 
wait and see, without proven superiority of one 
modality vs. the other; given the rarity of the truly 
localized disease, it is unlikely that such data will 
become available over the next years. In 
consideration of its high efficacy (with a 
consistent proportion of patients without relapse at 
15 years) and very low morbidity, modern RT 
maintains its role as a first choice treatment for the 
majority FL patients presenting with stage I-II 
disease at diagnosis. 
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